REGN Regeneron Pharmaceuticals Earnings and EPS analysis

EPS in 2025 (TTM): $41.77

Last Report Period Date: Mar 31, 2025

As of June 2025, REGN's trailing twelve months (TTM) EPS stands at $41.77, according to the latest financial reports. In 2024, the company recorded an earnings per share (EPS) of $40.9, which represents an increase compared to its EPS of $37.05 in 2023. REGN reported an EPS of $7.58 for the quarterly report ending on Mar 31, 2025.

For 2024, Regeneron Pharmaceuticals's EPS was $40.9, an increase of 10.4% from $37.05 in 2023. For the quarter ending Mar 31, 2025, the EPS was $7.58, showing a 13.1% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2025 is $41.77. In 2023, the annual EPS was $37.05, showing a decrease of 8.5% from 2022.

Over the last 12 months, Regeneron Pharmaceuticals has registered an EPS growth of 13.1% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -18.8% per year. Over the last 5 years, the company had an average EPS growth rate of 16.1%. When measured over a ten-year period, REGN's average EPS growth rate was 28.4%.